ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1581

End-of-Study Results from ACQUIRE: A Study Measuring Quality of Life, Treatment Preference, and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease Patients in Europe

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Joly, Dominique, Nephrology Department, Necker Hospital, Paris, France
  • Doll, Helen, Clinical Outcomes Solutions Ltd, Folkestone, United Kingdom
  • De Jong-Laird, Anne, Otsuka Pharmaceutical Europe Ltd, Wexham, Buckinghamshire, United Kingdom
  • Kabra, Madhusudan, Otsuka Pharmaceutical Europe Ltd, Wexham, Buckinghamshire, United Kingdom
Background

Little is known about health-related quality of life (HRQoL) and patient (pt) reported outcome (PRO) measures in early autosomal dominant polycystic kidney disease (ADPKD), and longitudinal studies are lacking.

Methods

ACQUIRE (NCT02848521) was a prospective, non-interventional, real-world observational study in pts with early and rapidly progressing ADPKD (chronic kidney disease [CKD] stages 1–3) across 7 European countries. The primary objective was to measure changes in Physical Health Composite Scale (PCS) scores of the 12-item Short Form Health Survey (SF-12) over 18 months. Other objectives included changes in SF-12 Mental Health Composite Scale (MCS) scores, ADPKD-specific PROs including the ADPKD-Impact Scale (IS), -Urinary Impact Scale (UIS) and -Pain & Discomfort Scale (PDS), and treatment satisfaction questionnaire (TSQM-9).

Results

Patient demographics were previously reported. Overall 305/403 (75.7%) were included in the PRO analysis set. Changes from baseline in SF-12 (PCS and MCS), ADPKD-IS (Physical and Emotional domains) and TSQM-9 (Global Satisfaction) through Month 18 are presented in Figure 1. CKD-1 pts and pts not receiving tolvaptan reported the lowest treatment satisfaction. No consistent changes were observed for ADPKD-UIS and ADPKD-PDS (not shown).

Conclusion

Over an 18-month timeframe, pts reported reduced scores in the PCS component of SF-12, deterioration in the physical components of ADPKD-IS and reduced treatment satisfaction. These data suggest that continued disease progression negatively impacts the HRQoL of pts with early stages of ADPKD and implies there may be current unmet treatment needs in this pt population.

Figure 1. Change from Baseline in PROs

Funding

  • Commercial Support